Randomised Comparisons, in Myeloma Patients of All Ages, of Thalidomide, Lenalidomide, Carfilzomib and Bortezomib Induction Combinations, and of Lenalidomide and Combination Lenalidomide Vorinostat as Maintenance (Myeloma XI)

Trial Profile

Randomised Comparisons, in Myeloma Patients of All Ages, of Thalidomide, Lenalidomide, Carfilzomib and Bortezomib Induction Combinations, and of Lenalidomide and Combination Lenalidomide Vorinostat as Maintenance (Myeloma XI)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Lenalidomide (Primary) ; Bortezomib; Cyclophosphamide; Dexamethasone; Melphalan; Thalidomide; Vorinostat
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms Myeloma-XI; UK NCRI Myeloma XI
  • Most Recent Events

    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 12 Dec 2017 Results of analysis assessing the impact of MRD on PFS amongst patients receiving maintenance or no further therapy presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 25 Jun 2017 Results assessing Lenalidomide Induction and Maintenance Therapy for Transplant Eligible Myeloma Patients, presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top